FDA advisors' scrutiny of MDMA therapy is 'temporary setback,' says Harvard researcher

Some Boston-area researchers said the decision by advisors to the U.S. Food and Drug Administration reflected challenges facing regulators as psychedelic treatments enter mainstream psychiatry.

Related Keywords

Boston ,Massachusetts ,United States ,Stephen Haggarty ,Deborah Becker ,Harvard Law School Petrie Flom Center ,Drug Administration ,Hospital Center ,Some Boston Area ,Lykos Therapeutics ,Mass General Hospital ,Mason Marks ,Psychedelics Law ,Harvard Law School ,Petrie Flom Center ,All Things Considered ,